Rebecca Barksdale, MD
Family Medicine · Greenville, SCNPI 1215915343
Payments from drug & device makers
Across 296 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$1K
- Lilly USA, LLC$663
- AbbVie$495
- Novo Nordisk$466
- AstraZeneca$387
- Pfizer$292
- plus $2K from 32 others
What the payments were for
- Food & beverage$5,869100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 38 | $1,457 |
| Lilly USA, LLC | 40 | $663 |
| AbbVie(2 entities) | 36 | $495 |
| Novo Nordisk | 32 | $466 |
| AstraZeneca | 24 | $387 |
| Pfizer | 18 | $292 |
| Antares Pharma, Inc. | 11 | $199 |
| Abbott | 9 | $170 |
| Johnson & Johnson | 7 | $162 |
| Medline Industries LP | 1 | $149 |
| Kerecis Limited | 1 | $144 |
| GSK | 7 | $118 |
| Bayer | 7 | $114 |
| Dexcom, Inc. | 5 | $109 |
| Amgen | 7 | $106 |
| Merck | 5 | $98 |
| Astellas Pharma US Inc | 4 | $94 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Boehringer Ingelheim | 5 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $53 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Eisai Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Novartis | 2 | $26 |
| Halozyme Inc | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Shire North American Group Inc | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $11 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$2,181
- INTEGRA DERMAL REGENERATION TEMPLATE$727
- PRIMATRIX$727
- Kerecis SurgiClose$576
- Kerecis GraftGuide$144
How this compares
$5,898 in reported general payments places this provider in the 85th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $150,702 |
| JardianceEmpagliflozin | 96 | $118,346 |
| JanuviaSitagliptin Phosphate | 62 | $57,876 |
| EliquisApixaban | 46 | $43,938 |
| LinzessLinaclotide | 41 | $38,486 |
| TrulicityDulaglutide | 31 | $35,200 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $26,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,312 |
| XareltoRivaroxaban | 32 | $24,858 |
| FarxigaDapagliflozin Propanediol | 24 | $24,003 |
| Victoza 3-PakLiraglutide | 20 | $23,809 |
| MounjaroTirzepatide | 16 | $22,760 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $22,009 |
| MyrbetriqMirabegron | 19 | $19,741 |
| ProliaDenosumab | 11 | $19,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $466 | $162,004149 claims |
| Boehringer IngelheimJardiance | $68 | $118,34696 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $387 | $63,48691 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $663 | $57,96047 claims |
| MerckJanuvia | $98 | $57,87662 claims |
| AbbVieLinzess, Savella | $495 | $44,81254 claims |
| PfizerEliquis | $292 | $43,93846 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $118 | $36,74751 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $94 | $26,61132 claims |
| Johnson & JohnsonXarelto | $162 | $24,85832 claims |
| AmgenProlia | $106 | $19,50411 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $1 | $9,68415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Greenville
- James FranklinGreenville$3.5M
- Jeffrey HarrisGreenville$3.4M
- Christopher DavisGreenville$2.7M
- Harlicia FarleyGreenville$1.1M
- James WallaceGreenville$708K
- Eric Garcia-TorresGreenville$102K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.